WCM Investment Management LLC Takes Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

WCM Investment Management LLC bought a new position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) in the third quarter, according to the company in its most recent filing with the SEC. The firm bought 60,170 shares of the company’s stock, valued at approximately $1,051,000.

Several other institutional investors have also recently added to or reduced their stakes in the company. New Covenant Trust Company N.A. acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $28,000. EntryPoint Capital LLC acquired a new stake in Teva Pharmaceutical Industries during the 1st quarter valued at $30,000. UMB Bank n.a. raised its position in Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock valued at $44,000 after purchasing an additional 2,067 shares during the last quarter. Beach Investment Counsel Inc. PA acquired a new position in Teva Pharmaceutical Industries in the second quarter worth $48,000. Finally, Byrne Asset Management LLC bought a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $52,000. 54.05% of the stock is owned by institutional investors.

Teva Pharmaceutical Industries Stock Down 1.5 %

Shares of TEVA stock opened at $17.11 on Wednesday. The firm’s 50 day moving average price is $17.91 and its two-hundred day moving average price is $17.18. Teva Pharmaceutical Industries Limited has a 52-week low of $8.55 and a 52-week high of $19.31. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on TEVA shares. JPMorgan Chase & Co. lifted their price target on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. Barclays boosted their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Finally, StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and a consensus target price of $19.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.